Treatment of metastatic melanoma by 24-hour DTIC infusions and hemibody irradiation.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108029
Title:
Treatment of metastatic melanoma by 24-hour DTIC infusions and hemibody irradiation.
Authors:
Thatcher, Nick; Anderson, Heather; James, R; Davenport, P; Craig, P
Abstract:
Forty-three patients with widely metastatic melanoma were studied. Visceral metastases were present in 79% of the patient group, including five patients with brain metastases. No patients were excluded because of "early death," etc., from analysis. All 43 patients received 24-hour DTIC infusions. Dosages for individual patients ranged from 350 mg/M2 to 2.5 g/M2, a maximum of 6 courses being given. A total of 155 courses was administered. Hemibody irradiation (HBI) was delivered after 1 or 3 courses of DTIC to the area of maximum disease in 23 patients. Fourteen of the 43 patients responded to DTIC chemotherapy (with one complete response), a response rate of 33%. Seven of the chemotherapy responders also responded in other sites to subsequent HBI, a response rate of 30% (7/23). No patient responded to HBI and not to DTIC. Median survival was 4 months (range, 1-15), and nine patients are still alive at 3 to 15 months. Toxicity was generally mild, although there was one possible treatment-related death. Further exploration of DTIC infusion chemotherapy and HBI would be of interest.
Affiliation:
Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester, England.
Citation:
Treatment of metastatic melanoma by 24-hour DTIC infusions and hemibody irradiation. 1986, 57 (11):2103-7 Cancer
Journal:
Cancer
Issue Date:
1-Jun-1986
URI:
http://hdl.handle.net/10541/108029
DOI:
10.1002/1097-0142(19860601)57:11<2103::AID-CNCR2820571102>3.0.CO;2-G
PubMed ID:
3697910
Type:
Article
Language:
en
ISSN:
0008-543X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nicken
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorJames, Ren
dc.contributor.authorDavenport, Pen
dc.contributor.authorCraig, Pen
dc.date.accessioned2010-07-21T10:13:49Z-
dc.date.available2010-07-21T10:13:49Z-
dc.date.issued1986-06-01-
dc.identifier.citationTreatment of metastatic melanoma by 24-hour DTIC infusions and hemibody irradiation. 1986, 57 (11):2103-7 Canceren
dc.identifier.issn0008-543X-
dc.identifier.pmid3697910-
dc.identifier.doi10.1002/1097-0142(19860601)57:11<2103::AID-CNCR2820571102>3.0.CO;2-G-
dc.identifier.urihttp://hdl.handle.net/10541/108029-
dc.description.abstractForty-three patients with widely metastatic melanoma were studied. Visceral metastases were present in 79% of the patient group, including five patients with brain metastases. No patients were excluded because of "early death," etc., from analysis. All 43 patients received 24-hour DTIC infusions. Dosages for individual patients ranged from 350 mg/M2 to 2.5 g/M2, a maximum of 6 courses being given. A total of 155 courses was administered. Hemibody irradiation (HBI) was delivered after 1 or 3 courses of DTIC to the area of maximum disease in 23 patients. Fourteen of the 43 patients responded to DTIC chemotherapy (with one complete response), a response rate of 33%. Seven of the chemotherapy responders also responded in other sites to subsequent HBI, a response rate of 30% (7/23). No patient responded to HBI and not to DTIC. Median survival was 4 months (range, 1-15), and nine patients are still alive at 3 to 15 months. Toxicity was generally mild, although there was one possible treatment-related death. Further exploration of DTIC infusion chemotherapy and HBI would be of interest.en
dc.language.isoenen
dc.subjectCancer Metastasisen
dc.subjectSkin Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshDacarbazine-
dc.subject.meshEvaluation Studies as Topic-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMelanoma-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshRadiotherapy Dosage-
dc.subject.meshSkin Neoplasms-
dc.subject.meshTime Factors-
dc.titleTreatment of metastatic melanoma by 24-hour DTIC infusions and hemibody irradiation.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester, England.en
dc.identifier.journalCanceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.